232 related articles for article (PubMed ID: 25132263)
1. BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin.
Paul BT; Blanchard Z; Ridgway M; ElShamy WM
Oncogene; 2015 Jun; 34(23):3036-52. PubMed ID: 25132263
[TBL] [Abstract][Full Text] [Related]
2. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
3. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells.
Chock KL; Allison JM; Shimizu Y; ElShamy WM
Cancer Res; 2010 Nov; 70(21):8782-91. PubMed ID: 20940403
[TBL] [Abstract][Full Text] [Related]
4. T-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin.
Dziegielewska B; Casarez EV; Yang WZ; Gray LS; Dziegielewski J; Slack-Davis JK
Mol Cancer Ther; 2016 Mar; 15(3):460-70. PubMed ID: 26832797
[TBL] [Abstract][Full Text] [Related]
5. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
Sun C; Li N; Yang Z; Zhou B; He Y; Weng D; Fang Y; Wu P; Chen P; Yang X; Ma D; Zhou J; Chen G
J Natl Cancer Inst; 2013 Nov; 105(22):1750-8. PubMed ID: 24168967
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy.
He J; Yu JJ; Xu Q; Wang L; Zheng JZ; Liu LZ; Jiang BH
Autophagy; 2015; 11(2):373-84. PubMed ID: 25650716
[TBL] [Abstract][Full Text] [Related]
7. JNK- and Akt-mediated Puma expression in the apoptosis of cisplatin-resistant ovarian cancer cells.
Zhao Z; Wang J; Tang J; Liu X; Zhong Q; Wang F; Hu W; Yuan Z; Nie C; Wei Y
Biochem J; 2012 Jun; 444(2):291-301. PubMed ID: 22394200
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.
Sasano T; Mabuchi S; Kuroda H; Kawano M; Matsumoto Y; Takahashi R; Hisamatsu T; Sawada K; Hashimoto K; Isobe A; Testa JR; Kimura T
Mol Cancer Res; 2015 Apr; 13(4):795-806. PubMed ID: 25519148
[TBL] [Abstract][Full Text] [Related]
9. Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1.
Baloch T; López-Ozuna VM; Wang Q; Matanis E; Kessous R; Kogan L; Yasmeen A; Gotlieb WH
BMC Cancer; 2019 Jan; 19(1):44. PubMed ID: 30630446
[TBL] [Abstract][Full Text] [Related]
10. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
Yue P; Zhang X; Paladino D; Sengupta B; Ahmad S; Holloway RW; Ingersoll SB; Turkson J
Oncogene; 2012 May; 31(18):2309-22. PubMed ID: 21909139
[TBL] [Abstract][Full Text] [Related]
11. BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma.
Ibrahim N; He L; Leong CO; Xing D; Karlan BY; Swisher EM; Rueda BR; Orsulic S; Ellisen LW
Cancer Res; 2010 Sep; 70(18):7155-65. PubMed ID: 20807817
[TBL] [Abstract][Full Text] [Related]
12. ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts.
Washington MN; Suh G; Orozco AF; Sutton MN; Yang H; Wang Y; Mao W; Millward S; Ornelas A; Atkinson N; Liao W; Bast RC; Lu Z
Cell Death Dis; 2015 Aug; 6(8):e1836. PubMed ID: 26247722
[TBL] [Abstract][Full Text] [Related]
13. 8‑bromo‑7‑methoxychrysin induces apoptosis by regulating Akt/FOXO3a pathway in cisplatin‑sensitive and resistant ovarian cancer cells.
Ding Q; Chen Y; Zhang Q; Guo Y; Huang Z; Dai L; Cao S
Mol Med Rep; 2015 Oct; 12(4):5100-8. PubMed ID: 26151347
[TBL] [Abstract][Full Text] [Related]
14. [Influence of mifepristone on DNA repair genes and cisplatin sensitivity in human ovarian cancer drug-resistance cells].
Liu GY; Qu QX; Mi RR; Qi J
Zhonghua Fu Chan Ke Za Zhi; 2008 Feb; 43(2):132-5. PubMed ID: 18683754
[TBL] [Abstract][Full Text] [Related]
15. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
Yan X; Fraser M; Qiu Q; Tsang BK
Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436
[TBL] [Abstract][Full Text] [Related]
16. Suppression of anoikis by the neurotrophic receptor TrkB in human ovarian cancer.
Yu X; Liu L; Cai B; He Y; Wan X
Cancer Sci; 2008 Mar; 99(3):543-52. PubMed ID: 18201274
[TBL] [Abstract][Full Text] [Related]
17. Aurora-A/SOX8/FOXK1 signaling axis promotes chemoresistance via suppression of cell senescence and induction of glucose metabolism in ovarian cancer organoids and cells.
Sun H; Wang H; Wang X; Aoki Y; Wang X; Yang Y; Cheng X; Wang Z; Wang X
Theranostics; 2020; 10(15):6928-6945. PubMed ID: 32550913
[No Abstract] [Full Text] [Related]
18. EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1.
Li T; Cai J; Ding H; Xu L; Yang Q; Wang Z
Cancer Biol Ther; 2014 Mar; 15(3):271-8. PubMed ID: 24335192
[TBL] [Abstract][Full Text] [Related]
19. [Effects of Zengmian Yiliu Recipe combined cisplatin on the tumor inhibition rate in platinum-resistant ovarian cancer].
Qi C; Zhang QH; Li JX
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Jun; 32(6):817-21. PubMed ID: 22978111
[TBL] [Abstract][Full Text] [Related]
20. FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells.
Choi EJ; Seo EJ; Kim DK; Lee SI; Kwon YW; Jang IH; Kim KH; Suh DS; Kim JH
Oncotarget; 2016 Jan; 7(3):3506-19. PubMed ID: 26654944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
